Market Place
Sourcing Support
Pharmacosmos And G1 Therapeutics Close Tender Offer
18 Sep 2024 //
GLOBENEWSWIRE
Pharmacosmos And G1 Therapeutics Announce HSR Waiting Period End
05 Sep 2024 //
GLOBENEWSWIRE
G1 Therapeutics Provides Q2 2024 Results And Operational Highlights
08 Aug 2024 //
GLOBENEWSWIRE
Pharmacosmos Picks Up G1 Therapeutics, FDA-Approved Drug Cosela In Worth $405M
08 Aug 2024 //
FIERCE PHARMA
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2024 //
GLOBENEWSWIRE
G1 Therapeutics To Release Q2 2024 Results On August 8
25 Jul 2024 //
GLOBENEWSWIRE
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
G1 Therapeutics Fails Late-Stage Breast Cancer Trial
25 Jun 2024 //
BIOSPACE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
05 Jun 2024 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
G1 Therapeutics` stock sinks nearly 40% on PhIII readout delay
13 Feb 2024 //
ENDPTS
G1 Therapeutics Provides Corporate Update at 42nd Annual J.P. Morgan Conference
08 Jan 2024 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jan 2024 //
GLOBENEWSWIRE
G1 Therapeutics Presents New Post Hoc Analyses
05 Dec 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Presentation at San Antonio Breast Cancer Symposium
29 Nov 2023 //
GLOBENEWSWIRE
G1 Therapeutics Provides Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Data Indicate Trilaciclib Reduces Hospitalizations and Myelosuppressive Events
27 Oct 2023 //
GLOBENEWSWIRE
G1 Therapeutics to Release Third Quarter 2023 Financial Results
18 Oct 2023 //
GLOBENEWSWIRE
G1 Therapeutics COSELA Recommended in Updated Small Cell Lung Cancer Guidelines
18 Oct 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Presentations at the 2023 ASCO Quality Care Symposium
16 Oct 2023 //
GLOBENEWSWIRE
G1 Therapeutics to Participate in H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2023 //
GLOBENEWSWIRE
Trilaciclib Increases Pool of Memory T Cells in Tumor Microenvironment
04 Jun 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
22 May 2023 //
GLOBENEWSWIRE
New Study Confirms Consistent Risk of Myelosuppression Across All Patients
16 May 2023 //
GLOBENEWSWIRE
G1 Therapeutics reports preliminary results from Phase II trial of trilaciclib
11 May 2023 //
CLINICAL TRIALS ARENA
G1 Therapeutics to Participate in 22nd Annual Needham Healthcare Conference
11 Apr 2023 //
GLOBENEWSWIRE
G1 sheds staff while Sorrento WARNs of layoffs
02 Mar 2023 //
FIERCE BIOTECH
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
GLOBENEWSWIRE
G1 Therapeutics to halt drug trial in colon cancer, shares plunge
14 Feb 2023 //
REUTERS
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2023 //
GLOBENEWSWIRE
G1 Therapeutics to Participate in 2023 B. Riley Securities 3rd Annual Conference
11 Jan 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Readouts from PII & PIII Trials of Trilaciclib
09 Jan 2023 //
GLOBENEWSWIRE
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial
04 Jan 2023 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2022 //
GLOBENEWSWIRE
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
23 Nov 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Closing of Offering of Common Stock
22 Nov 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Pricing of Offering of Common Stock
17 Nov 2022 //
GLOBENEWSWIRE
G1 Therapeutics Prices Public Offering Of 7.70 Mln Shares At $6.50/shr
17 Nov 2022 //
NASDAQ
G1 Therapeutics Provides Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2022 //
GLOBENEWSWIRE
G1 Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin
26 Oct 2022 //
GLOBENEWSWIRE
G1 Therapeutics to Release Q3 2022 Financial Results
19 Oct 2022 //
GLOBENEWSWIRE
G1 Therapeutics Completes Enrollment in Global Ph3 Trial of Trilaciclib
10 Oct 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2022 //
GLOBENEWSWIRE
G1 Therapeutics Provides Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
G1 Therapeutics to Participate Virtually in the 2022 BTIG and Wedbush Conference
01 Aug 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
25 Jul 2022 //
GLOBENEWSWIRE
G1 Therapeutics To Release Second Quarter 2022 Financial Results
20 Jul 2022 //
PRESS RELEASE
COSELA Approved in China to Decrease Incidence of Myelosuppression in ES-SCLC
13 Jul 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
28 Jun 2022 //
GLOBENEWSWIRE
G1 Therapeutics Completes Enrollment in PIII Trial of Trilaciclib in mCC
13 Jun 2022 //
GLOBENEWSWIRE
